The second study, involving 210 patients taking corticosteroids by mouth for their asthma, showed that in 70% of patients given Dupixent their condition improved to the extent that they could reduce their corticosteroid dose compared with 42% of those given placebo.Ī subsequent third study involved 408 children 6 to 11 years of age with severe asthma that was not adequately controlled by a combination of medium-to-high-dose inhaled corticosteroids and other medicines. After 12 weeks of treatment, Dupixent improved patients’ FEV 1 (the maximum volume of air a person can breathe out in one second) by 320 ml (for 200 mg Dupixent) or 340 ml (for 300 mg Dupixent) compared with 180 ml and 210 ml for placebo. In the first study, involving 1,902 patients aged 12 years or above, the number of severe flare-ups per year was 0.46 in patients taking 200 mg Dupixent and 0.52 in patients taking 300 mg Dupixent, compared with 0.87 or 0.97 in patients given placebo. Overall 53% of patients (44 out of 83 patients) treated with Dupixent and a corticosteroid had an improvement in their skin of at least 75% compared with at least 11% (8 out of 11 patients) with placebo and a corticosteroid.ĭupixent was shown to reduce the number of exacerbations (flare-ups) of asthma during treatment in 2 main studies involving patients with asthma that was not adequately controlled by a combination of high-dose inhaled corticosteroids and other medicines. In addition, a study involving children between 6 months and less than 6 years of age with moderate to severe dermatitis showed that a 16-week treatment with Dupixent and a topical corticosteroid led to skin clearing in 28% of patients (23 out of 83 patients) compared with 4% of patients (3 out of 79 patients) given placebo and a topical corticosteroid. After 16 weeks, measures of severity showed that atopic dermatitis had cleared up or almost cleared up in around 33% of those given Dupixent with a topical corticosteroid compared with around 11% of those given placebo with a corticosteroid. In this study, after 16 weeks atopic dermatitis had cleared up or almost cleared up in around 24% of those given Dupixent every 2 weeks compared with around 2% of those given placebo.Ī further study looked at 367 children between 6 and 12 years of age with severe atopic dermatitis in whom medicines applied to the skin had proved insufficient or were unsuitable. Taking the results of the other two studies together, 37% of patients treated with Dupixent every two weeks had clearing or almost clearing of their atopic dermatitis compared with 9% of patients on placebo.Ī study was also carried out in 251 adolescents aged from 12 to less than 18 years with moderate to severe atopic dermatitis. Dupixent or placebo was used on its own in the other two studies involving a total of 1,379 patients.Īfter 16 weeks of treatment, 39% of patients treated with Dupixent every two weeks in the first study showed clearing or almost clearing of their atopic dermatitis compared with 12% of patients on placebo. In the first study, which involved 740 patients, participants were given Dupixent or placebo, both in combination with a topical corticosteroid (a medicine for inflammation applied to the skin). eosinophilic oesophagitis (an allergic condition of the food pipe) in adults and children above 12 years of age who cannot take conventional treatment or for whom it is not working.ĭupixent contains the active substance dupilumab.ĭupixent was more effective than placebo (a dummy treatment) at reducing the extent and severity of atopic dermatitis in 3 main studies in adults with moderate to severe disease. It is used with or without topical (applied to the skin) corticosteroids.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |